![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
How Long Will I Live with Chronic Myelomonocytic Leukemia?
The life expectancy for someone with chronic myelomonocytic leukemia (CMML) can vary greatly depending on a number of factors, including the stage of the disease at diagnosis, the patient's overall health, certain chromosome changes, blood levels of lactate dehydrogenase (LDH) and the patient's age.
What do Statistics Say About the Life Expectancy for Someone with Chronic Myelomonocytic Leukemia?
According to the American Cancer Society, the median survival for patients with CMML is about 20-30 months. However, this is a median value, meaning that half of patients live longer than this, and half live less. Patients with CMML-1 tend to live longer than those with CMML-2. In one study of CMML patients diagnosed between 1975 and 2005, the median survival times with CMML-1 and CMML-2 were 20 months and 15 months, respectively. However, some patients lived much longer. About 20% of CMML-1 patients and about 10% of CMML-2 patients survived longer than 5 years. Also, patients with CMML-2 are more likely to go on to develop acute leukemia than patients with CMML-1. In the same study, 18% of CMML-1 patients and 63% of CMML-2 patients developed acute myeloid leukemia within 5 years of their CMML diagnosis.
It's important to note that these statistics are based on data from several years ago, and advancements in treatment may lead to better survival rates today.
What Factors Affect Prognosis for Chronic Myelomonocytic Leukemia?
- Age: Older patients generally have a poorer prognosis than younger ones.
- Overall health: Patients with other serious health conditions may have a poorer prognosis.
- Stage of the disease: Patients diagnosed at an earlier stage generally have a better prognosis.
- Response to treatment: Patients who respond well to treatment generally have a better prognosis.
- Genetic mutations: Certain genetic mutations can affect prognosis. For example, patients with the ASXL1 mutation generally have a poorer prognosis.
It's important to note that survival statistics are general trends and a patient's individual prognosis can vary greatly. Each patient's case is unique and should be discussed with their healthcare provider. Having a CMML specialist on your team provides you with the best way of truly understanding your prognosis. Visit HealthTree's CMML Specialist Directory to find a CMML expert near you.
At HealthTree, we’re laying the foundation for a future of more effective and personalized cures. HealthTree Cure Hub empowers patients with the information they need to be active participants in their care so they can live longer and better. Create a free account and become a Cure Contributor today!
SIGN IN / JOIN HEALTHTREE CURE HUB
Want to Learn More About Chronic Myelomonocytic Leukemia?
Keep reading HealthTree for Chronic Myelomonocytic Leukemia's 101 pages!
The life expectancy for someone with chronic myelomonocytic leukemia (CMML) can vary greatly depending on a number of factors, including the stage of the disease at diagnosis, the patient's overall health, certain chromosome changes, blood levels of lactate dehydrogenase (LDH) and the patient's age.
What do Statistics Say About the Life Expectancy for Someone with Chronic Myelomonocytic Leukemia?
According to the American Cancer Society, the median survival for patients with CMML is about 20-30 months. However, this is a median value, meaning that half of patients live longer than this, and half live less. Patients with CMML-1 tend to live longer than those with CMML-2. In one study of CMML patients diagnosed between 1975 and 2005, the median survival times with CMML-1 and CMML-2 were 20 months and 15 months, respectively. However, some patients lived much longer. About 20% of CMML-1 patients and about 10% of CMML-2 patients survived longer than 5 years. Also, patients with CMML-2 are more likely to go on to develop acute leukemia than patients with CMML-1. In the same study, 18% of CMML-1 patients and 63% of CMML-2 patients developed acute myeloid leukemia within 5 years of their CMML diagnosis.
It's important to note that these statistics are based on data from several years ago, and advancements in treatment may lead to better survival rates today.
What Factors Affect Prognosis for Chronic Myelomonocytic Leukemia?
- Age: Older patients generally have a poorer prognosis than younger ones.
- Overall health: Patients with other serious health conditions may have a poorer prognosis.
- Stage of the disease: Patients diagnosed at an earlier stage generally have a better prognosis.
- Response to treatment: Patients who respond well to treatment generally have a better prognosis.
- Genetic mutations: Certain genetic mutations can affect prognosis. For example, patients with the ASXL1 mutation generally have a poorer prognosis.
It's important to note that survival statistics are general trends and a patient's individual prognosis can vary greatly. Each patient's case is unique and should be discussed with their healthcare provider. Having a CMML specialist on your team provides you with the best way of truly understanding your prognosis. Visit HealthTree's CMML Specialist Directory to find a CMML expert near you.
At HealthTree, we’re laying the foundation for a future of more effective and personalized cures. HealthTree Cure Hub empowers patients with the information they need to be active participants in their care so they can live longer and better. Create a free account and become a Cure Contributor today!
SIGN IN / JOIN HEALTHTREE CURE HUB
Want to Learn More About Chronic Myelomonocytic Leukemia?
Keep reading HealthTree for Chronic Myelomonocytic Leukemia's 101 pages!
Get the latest thought leadership on your Chronic Myelomonocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811